We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
Read MoreHide Full Article
Key Takeaways
Altimmune has launched the global PERFORMA Phase III study to test pemvidutide in MASH.
Phase IIb data showed MASH resolution and signs of reduced liver scarring through 48 weeks.
Altimmune expects its cash runway to support operations into 2029 and has secured Phase III capacity.
Altimmune (ALT - Free Report) has moved pemvidutide into phase III development for metabolic dysfunction-associated steatohepatitis (MASH), shifting the program from mid-stage evidence to a pivotal global test.
The transition puts more weight on execution. Investors must now judge whether earlier efficacy signals, regulatory support and operational preparation can carry the program through a multi-year development window.
Altimmune Moves Pemvidutide Into Phase III
The global PERFORMA study is evaluating pemvidutide in adults with MASH and moderate-to-severe liver fibrosis. The randomized, placebo-controlled trial will assess MASH resolution, fibrosis improvement and liver-related outcomes.
PERFORMA includes two cohorts and an interim analysis intended to support a potential accelerated-approval pathway. Altimmune expects 52-week data in 2029, while final approval would depend on liver-related events at about 60 months.
ALT Enters Phase III With Supportive MASH Data
Phase IIb testing showed statistically significant MASH resolution without worsening fibrosis at 24 weeks. That effect was sustained through 48 weeks.
Pemvidutide also showed signs of reducing liver scarring by week 48. Markers of liver damage and inflammation continued improving over time, alongside weight loss.
Altimmune's Dual-Agonist Profile Drives the Thesis
Pemvidutide combines balanced 1:1 glucagon and GLP-1 receptor activity. Glucagon acts directly on the liver, while GLP-1 supports weight loss through appetite reduction and may provide anti-inflammatory benefits.
Altimmune also uses its EuPort technology to slow absorption. The company believes this may improve tolerability and reduce gastrointestinal side effects, which could help patients remain on long-term treatment.
ALT's Regulatory Status Could Support Development
The FDA has granted pemvidutide Breakthrough Therapy Designation for MASH. The candidate also has Fast Track designation for the same indication.
Those designations sit alongside PERFORMA's interim-analysis framework as Altimmune pursues a registrational pathway. The pivotal study remains the central test of whether the phase IIb profile can translate into late-stage results.
Altimmune Has Cash and Manufacturing in Place
Altimmune ended June 2026 with $519 million in cash, cash equivalents and short-term investments, up from $332 million at the end of March. Management expects the cash runway to support operations into 2029.
The company has also secured manufacturing capacity for the global phase III MASH study, with room to scale further if needed. That preparation reduces near-term supply and program-execution concerns.
PERFORMA enrollment is expected to take 18 to 24 months, with management targeting the lower end. Any slippage could extend the pivotal timeline before investors receive the key clinical readout.
Competition is another constraint. The field spans GLP-1 drugs, dual and triple agonists, FGF21 therapies and other mechanisms. Novo Nordisk (NVO - Free Report) has advanced semaglutide through phase III MASH testing. Eli Lilly and Company (LLY - Free Report) is testing tirzepatide and retatrutide in a phase III liver-outcomes program for high-risk metabolic dysfunction-associated steatotic liver disease.
ALT's Momentum Score Adds Support but Not Conviction
The phase III launch is an important clinical milestone, but Altimmune still faces a long path to the 2029 data. Successful enrollment, trial execution and differentiation in a crowded market will determine how much value investors ultimately assign to pemvidutide.
ALT currently carries a Zacks Rank #3 (Hold) and a Momentum Score of A. Its Value Score of F, Growth Score of F and VGM Score of F show a much weaker profile across the other Zacks Style Score dimensions. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
The A Momentum Score signals comparatively favorable momentum characteristics, but Style Scores are designed to complement the Zacks Rank. With a #3 Rank and F grades in Value, Growth and VGM, ALT's current indicators remain mixed rather than broadly supportive.
View the Zacks #1 Rank List
Image: Bigstock
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
Key Takeaways
Altimmune (ALT - Free Report) has moved pemvidutide into phase III development for metabolic dysfunction-associated steatohepatitis (MASH), shifting the program from mid-stage evidence to a pivotal global test.
The transition puts more weight on execution. Investors must now judge whether earlier efficacy signals, regulatory support and operational preparation can carry the program through a multi-year development window.
Altimmune Moves Pemvidutide Into Phase III
The global PERFORMA study is evaluating pemvidutide in adults with MASH and moderate-to-severe liver fibrosis. The randomized, placebo-controlled trial will assess MASH resolution, fibrosis improvement and liver-related outcomes.
PERFORMA includes two cohorts and an interim analysis intended to support a potential accelerated-approval pathway. Altimmune expects 52-week data in 2029, while final approval would depend on liver-related events at about 60 months.
ALT Enters Phase III With Supportive MASH Data
Phase IIb testing showed statistically significant MASH resolution without worsening fibrosis at 24 weeks. That effect was sustained through 48 weeks.
Pemvidutide also showed signs of reducing liver scarring by week 48. Markers of liver damage and inflammation continued improving over time, alongside weight loss.
Altimmune's Dual-Agonist Profile Drives the Thesis
Pemvidutide combines balanced 1:1 glucagon and GLP-1 receptor activity. Glucagon acts directly on the liver, while GLP-1 supports weight loss through appetite reduction and may provide anti-inflammatory benefits.
Altimmune also uses its EuPort technology to slow absorption. The company believes this may improve tolerability and reduce gastrointestinal side effects, which could help patients remain on long-term treatment.
ALT's Regulatory Status Could Support Development
The FDA has granted pemvidutide Breakthrough Therapy Designation for MASH. The candidate also has Fast Track designation for the same indication.
Those designations sit alongside PERFORMA's interim-analysis framework as Altimmune pursues a registrational pathway. The pivotal study remains the central test of whether the phase IIb profile can translate into late-stage results.
Altimmune Has Cash and Manufacturing in Place
Altimmune ended June 2026 with $519 million in cash, cash equivalents and short-term investments, up from $332 million at the end of March. Management expects the cash runway to support operations into 2029.
The company has also secured manufacturing capacity for the global phase III MASH study, with room to scale further if needed. That preparation reduces near-term supply and program-execution concerns.
Altimmune, Inc. Price and Consensus
Altimmune, Inc. price-consensus-chart | Altimmune, Inc. Quote
ALT's 2029 Readout Leaves a Long Execution Window
PERFORMA enrollment is expected to take 18 to 24 months, with management targeting the lower end. Any slippage could extend the pivotal timeline before investors receive the key clinical readout.
Competition is another constraint. The field spans GLP-1 drugs, dual and triple agonists, FGF21 therapies and other mechanisms. Novo Nordisk (NVO - Free Report) has advanced semaglutide through phase III MASH testing. Eli Lilly and Company (LLY - Free Report) is testing tirzepatide and retatrutide in a phase III liver-outcomes program for high-risk metabolic dysfunction-associated steatotic liver disease.
ALT's Momentum Score Adds Support but Not Conviction
The phase III launch is an important clinical milestone, but Altimmune still faces a long path to the 2029 data. Successful enrollment, trial execution and differentiation in a crowded market will determine how much value investors ultimately assign to pemvidutide.
ALT currently carries a Zacks Rank #3 (Hold) and a Momentum Score of A. Its Value Score of F, Growth Score of F and VGM Score of F show a much weaker profile across the other Zacks Style Score dimensions. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
The A Momentum Score signals comparatively favorable momentum characteristics, but Style Scores are designed to complement the Zacks Rank. With a #3 Rank and F grades in Value, Growth and VGM, ALT's current indicators remain mixed rather than broadly supportive.